Yahoo
Swiss - Delayed Quote CHF

Sandoz Group AG (SDZ.SW)

84.46 +0.68 (+0.81%)
At close: November 9 at 5:31:02 PM GMT+1
Chart Range Bar
Loading chart for SDZ.SW
  • Previous Close 83.78
  • Open 84.00
  • Bid --
  • Ask --
  • Day's Range 84.00 - 85.32
  • 52 Week Range 52.54 - 85.62
  • Volume 839,451
  • Avg. Volume 1,318,126
  • Market Cap (intraday) 36.545B
  • Beta (5Y Monthly) 0.40
  • PE Ratio (TTM) 72.19
  • EPS (TTM) 1.17
  • Earnings Date --
  • Forward Dividend & Yield 0.80 (0.95%)
  • 1y Target Est 79.58
  • Moby Rating Neutral

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.

www.sandoz.com

20,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

SDZ.SW
47.80%
MSCI WORLD (^990100-USD-STRD)
8.93%

1-Year Return

SDZ.SW
61.66%
MSCI WORLD (^990100-USD-STRD)
12.28%

3-Year Return

SDZ.SW
266.90%
MSCI WORLD (^990100-USD-STRD)
68.13%

5-Year Return

SDZ.SW
186.31%
MSCI WORLD (^990100-USD-STRD)
50.00%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 3B
Earnings --
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q2

FY26

0
1B
2B
3B
0.0%

Analyst Insights

View More

Analyst Price Targets

59.15 Low
79.58 Average
84.46 Current
108.80 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.53%

  • Return on Assets (ttm)

    3.05%

  • Return on Equity (ttm)

    7.25%

  • Revenue (ttm)

    11.68B

  • Net Income Avi to Common (ttm)

    646M

  • Diluted EPS (ttm)

    1.17

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.27B

  • Total Debt/Equity (mrq)

    68.92%

  • Levered Free Cash Flow (ttm)

    1.37B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: